Details

Autor(en) / Beteiligte

• Neafsey, Daniel E
• Juraska, Michal
• Bedford, Trevor
• Benkeser, David
• Valim, Clarissa
• Griggs, Allison
• Lievens, Marc
• Abdulla, Salim
• Adjei, Samuel
• Agbenyega, Tsiri
• Agnandji, Selidji T
• Aide, Pedro
• Anderson, Scott
• Ansong, Daniel
• Aponte, John J
• Asante, Kwaku Poku
• Bejon, Philip
• Birkett, Ashley J
• Bruls, Myriam
• Connolly, Kristen M
• D’Alessandro, Umberto
• Dobaño, Carlota
• Gesase, Samwel
• Greenwood, Brian
• Grimsby, Jonna
• Tinto, Halidou
• Hamel, Mary J
• Hoffman, Irving
• Kamthunzi, Portia
• Kariuki, Simon
• Kremsner, Peter G
• Leach, Amanda
• Lell, Bertrand
• Lennon, Niall J
• Lusingu, John
• Marsh, Kevin
• Martinson, Francis
• Molel, Jackson T
• Moss, Eli L
• Njuguna, Patricia
• Ockenhouse, Christian F
• Ogutu, Bernhards Ragama
• Otieno, Walter
• Otieno, Lucas
• Otieno, Kephas
• Owusu-Agyei, Seth
• Park, Daniel J
• Pellé, Karell
• Robbins, Dana
• Russ, Carsten
• Ryan, Elizabeth M
• Sacarlal, Jahit
• Sogoloff, Brian
• Sorgho, Hermann
• Tanner, Marcel
• Theander, Thor
• Valea, Innocent
• Volkman, Sarah K
• Yu, Qing
• Lapierre, Didier
• Birren, Bruce W
• Gilbert, Peter B
• Wirth, Dyann F

Titel

Genetic Diversity and Protective Efficacy of the RTS,S/AS01 Malaria Vaccine

Ist Teil von

• The New England journal of medicine, 2015-11, Vol.373 (21), p.2025-2037

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Quelle

MEDLINE

Beschreibungen/Notizen

• There is a tremendous need for a malaria vaccine. By means of a sieve analysis, the RTS,S/AS01 candidate vaccine, which is in advanced clinical development, was shown to have improved vaccine efficacy against genetically matched versus mismatched infecting malaria strains. Malaria induces substantial morbidity and mortality worldwide 1 and has proved to be a challenge for vaccine-development efforts. The recently renewed effort to control, eliminate, and hopefully eradicate malaria will have a greater likelihood of success if a vaccine can be combined with other intervention methods, such as drug-administration campaigns and insect-vector control. 2 , 3 The most advanced candidate vaccine for protection against Plasmodium falciparum malaria infection, RTS,S/AS01, is a monovalent recombinant protein vaccine that targets a fragment of the circumsporozoite protein parasite antigen. RTS,S/AS01 was evaluated in a large randomized, controlled, phase 3 trial, conducted at 11 study sites in Africa . . .